Subject(s)
Lymphadenopathy/pathology , Photosensitivity Disorders/pathology , Steroids/therapeutic use , Adolescent , COVID-19/diagnosis , COVID-19/epidemiology , COVID-19/virology , Hair , Humans , Male , Photosensitivity Disorders/diagnosis , Photosensitivity Disorders/drug therapy , SARS-CoV-2/genetics , Seasons , Steroids/administration & dosage , Treatment OutcomeSubject(s)
Dermatitis, Seborrheic/diagnosis , Emollients/therapeutic use , Genital Neoplasms, Female , Gynecological Examination , Lichen Planus/diagnosis , Pruritus Vulvae , Psoriasis/diagnosis , Symptom Assessment , Biopsy/methods , Dermatitis, Contact/complications , Dermatitis, Contact/diagnosis , Diagnosis, Differential , Female , Genital Neoplasms, Female/diagnosis , Genital Neoplasms, Female/pathology , Gynecological Examination/methods , Gynecological Examination/psychology , Humans , Patient Care Management/methods , Pruritus Vulvae/diagnosis , Pruritus Vulvae/physiopathology , Pruritus Vulvae/psychology , Sexual Health , Symptom Assessment/methods , Symptom Assessment/psychologySubject(s)
Melanoma/mortality , Skin Neoplasms/mortality , Aged , Aged, 80 and over , Female , Humans , Incidence , Male , Mortality/trends , Survival Analysis , United Kingdom/epidemiologyABSTRACT
An 8-year-old boy presented with eczematous skin lesions, recurrent otitis media and unexplained pyrexias. X-linked agammaglobulinaemia was diagnosed and treatment commenced with intravenous immunoglobulin replacement therapy. X-linked agammaglobulinaemia (XLA) is a primary immunodeficiency syndrome associated with a deficiency of B lymphocytes, caused by a defect in the expression of Bruton's tyrosine kinase. It affects only boys and usually presents before the age of 2 years with recurrent bacterial sinopulmonary infections. IgG levels are usually <2 g/L (normal range 5.4-16.1) and IgM and IgA are usually undetectable. The commonest cutaneous features of XLA are pyogenic skin infections; however, eczema can occur with increased frequency. We report a child who presented with multiple discrete eczematous lesions who subsequently developed eczematous exacerbations several days after administration of intravenous immunoglobulin (IVIg) replacement therapy.